Trilotab 60 mg chewable tablets for dogs

Authorised

- Trilostane

Product identification

Medicine name:
Trilotab 60 mg chewable tablets for dogs
Trilotab vet, 60 mg närimistabletid koertele

Active substance:
Trilostane

Target species:
Dog

Route of administration:
Oral use

Product details

Active substance and strength:
Trilostane
60.00 milligram(s) / 1.00 Tablet

Pharmaceutical form:
Chewable tablet

Withdrawal period by route of administration:

Oral use:

- **Dog**

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QH02CA01

Legal status of supply:
Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Estonia

Available in:
Estonia

Package description:
Aluminium-PVC/Aluminium/oPA blisters, containing 10 tablets. Cardboard box of 10 blisters of 10 tablets
Aluminium-PVC/Aluminium/oPA blisters, containing 10 tablets. Cardboard box of 3 blister of 10 tablets

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Generic application (Article 18 of Regulation (EU) 2019/6)

Marketing authorisation holder:
CP-Pharma Handelsgesellschaft mbH

Marketing authorisation date:
3/09/2023

Manufacturing sites for batch release:
CP-Pharma Handelsgesellschaft mbH

Responsible authority:
State Agency Of Medicines

Authorisation number:
1122823

Date of authorisation status change:
3/09/2023

Reference member state:
Netherlands

Procedure number:
NL/V/0373/003

Concerned member states:
Austria Belgium Czechia Denmark Estonia Finland France Germany Hungary Ireland Italy Latvia Lithuania Poland Portugal Slovakia Spain Sweden United Kingdom (Northern Ireland)

Generic of:
600000089372

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.

Combined File of all Documents

PuAR Trilotab NL_V_0373_001-005_DC 2023-08.pdf
